Incyte wins FDA approval for Niktimvo, considers future - Delaware Business Times
Incyte and Syndax Pharmaceuticals secure FDA approval for Niktimvo, a treatment for chronic graft-versus-host disease, with potential sales of $650 million.
Reference News
Incyte wins FDA approval for Niktimvo, considers future - Delaware Business Times
Incyte and Syndax Pharmaceuticals secure FDA approval for Niktimvo, a treatment for chronic graft-versus-host disease, with potential sales of $650 million.